Arsenic Trioxide and Icariin Show Synergistic Anti-leukemic Activity

Cell Biochemistry and Biophysics

Volumn 73, Issue 1, 2015, Pages 213-219

  Wang, Zhi ^a   Zhang, Hong ^a   Dai, Liling ^a   Song, Tongguo ^b   Li, Ping ^a   Liu, Yali ^a   Wang, Luning ^a  

^a QINGDAO UNIVERSITY   (China)

^b Emergency Department of Qingdao Emergency Center   (China)

Author keywords

APL; ATO; Icariin; ROS; Synergistic effect

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; FLAVONOID; ICARIIN; ORGANOARSENIC DERIVATIVE; OXIDE; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; PROMYELOCYTIC LEUKEMIA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FLAVONOIDS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MEMBRANE POTENTIAL, MITOCHONDRIAL; OXIDES; REACTIVE OXYGEN SPECIES;

EID: 84939254424     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-015-0660-2     Document Type: Article

References (36)

1. Estey, E., & Dohner, H. (2006). Acute myeloid leukaemia. Lancet,368(9550), 1894–1907.
2. Rogers, C. S., et al. (2014). Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells. Experimental Hematology and Oncology,3(1), 9.
3. Borrow, J., et al. (1990). Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science,249(4976), 1577–1580.
4. de The, H., et al. (1990). The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature,347(6293), 558–561.
5. Cyranoski, D. (2007). Arsenic patent keeps drug for rare cancer out of reach of many. Nature Medicine,13(9), 1005.
6. Shen, Z. X., et al. (1997). Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood,89(9), 3354–3360.
7. Soignet, S. L., et al. (1998). Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New England Journal of Medicine,339(19), 1341–1348.
8. Fox, E., et al. (2008). Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood,111(2), 566–573.
9. Ebinger, M., et al. (2011). Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy. Pediatric Hematology and Oncology,28(4), 334–337.
10. Douer, D., & Tallman, M. S. (2005). Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies. Journal of Clinical Oncology,23(10), 2396–2410.
11. Sanz, M. A., et al. (2009). Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood,113(9), 1875–1891.
12. Li, S., et al. (2010). Icariin, a natural flavonol glycoside, induces apoptosis in human hepatoma SMMC-7721 cells via a ROS/JNK-dependent mitochondrial pathway. Cancer Letters,298(2), 222–230.
13. Lin, C. C., et al. (2004). Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukaemia cell growth. Clinical and Experimental Pharmacology and Physiology,31(1–2), 65–69.
14. Wang, Y., et al. (2010). Icariin exterts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. European Journal of Pharmacology,635(1–3), 40–48.
15. Zhang, D. C., et al. (2013). Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-κB. Acta Pharmacologica Sinica,34(2), 301–308.
16. Yang, L., et al. (2014). Synergistic anti-cancer effects of Icariin and temozolomide in glioblastoma. Cell Biochemistryand Biophysics. 2014. doi:10.1007/s12013-014-0360-3.
17. Shi, D. B., et al. (2014). Icariin-mediated inhibition of NF-κB activity enhances the in vitro and in vivo antitumour effect of 5-fluorouracil in colorectal cancer. Cell Biochemistry and Biophysics,69(3), 523–530.
18. Li, W., et al. (2014). Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cell Biochemistry and Biophysics,68(2), 427–436.
19. Chou, T. C., & Talalay, P. (1984). Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation,22, 27–55.
20. Wang, D., et al. (2008). Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. International Journal of Urology,15(5), 435–441.
21. Liou, G. Y., & Storz, P. (2010). Reactive oxygen species in cancer. Free Radical Research,44(5), 479–496.
22. Chen, Y., et al. (2011). Icariin and its pharmaceutical efficacy: Research progress of molecular mechanism. Zhong Xi Yi Jie He Xue Bao,9(11), 1179–1184.
23. Huang, X., Zhu, D., & Lou, Y. (2007). A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. European Journal of Pharmacology,564(1–3), 26–36.
24. Wang, Y., et al. (2010). Icariin exterts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. European Journal of Pharmacology,635(1–3), 40–48.
25. Wang, Q., et al. (2011). Icariin induces apoptosis in mouse MLTC-10 Leydig tumor cells through activation of the mitochondrial pathway and down-regulation of the expression of piwil4. International Journal of Oncology,39(4), 973–980.
26. Tatham, M. H., et al. (2008). RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nature Cell Biology,10(5), 538–546.
27. Chen, G. Q., et al. (1997). Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood,89(9), 3345–3353.
28. Yang, C. H., et al. (1999). Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. British Journal of Cancer,81(5), 796–799.
29. Chou, W. C., et al. (2004). Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proceedings of the National Academy of Sciences of the United States of America,101(13), 4578–4583.
30. Fan, Y., et al. (2014). Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity. PLoS ONE,9(8), e105890.
31. Benbijja, M., Mellouk, A., & Bobe, P. (2014). Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface. Molecular Cancer,13, 251.
32. Wo, Y. B., et al. (2008). Reactive oxygen species involved in prenylflavonoids, icariin and icaritin, initiating cardiac differentiation of mouse embryonic stem cells. Journal of Cellular Biochemistry,103(5), 1536–1550.
33. Ding, L., et al. (2008). Involvement of p38MAPK and reactive oxygen species in icariin-induced cardiomyocyte differentiation of murine embryonic stem cells in vitro. Stem Cells and Development,17(4), 751–760.
34. Zeng, K. W., et al. (2010). Icariin attenuates lipopolysaccharide-induced microglial activation and resultant death of neurons by inhibiting TAK1/IKK/NF-κB and JNK/p38 MAPK pathways. International Immunopharmacology,10(6), 668–678.
35. Xiao-Hong, D., et al. (2013). Icariin delays homocysteine-induced endothelial cellular senescence involving activation of the PI3K/AKT-eNOS signaling pathway. Pharmaceutical Biology,51(4), 433–440.
36. Zhou, H., et al. (2014). Icariin attenuates angiotensin II-induced hypertrophy and apoptosis in H9c2 cardiomyocytes by inhibiting reactive oxygen species-dependent JNK and p38 pathways. Experimental and Therapeutic Medicine,7(5), 1116–1122.